As of November 6, 2026, Amylyx Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: AMLX); its largest reported holder is Fidelity (FMR), with 15% on Schedule 13G/A of February 5, 2026, then Perceptive Advisors (7.5%). The largest insider holding is Joshua B. Cohen, the chief executive and a director, with 3,613,123 shares (2.8% of shares outstanding), per Form 4 of September 14, 2026 (Schedule 13G/A, February 5, 2026).
Is this your company?
About to sign with, pay or invest in Amylyx Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Amylyx Pharmaceuticals, Inc. a real, registered company?
- Amylyx Pharmaceuticals, Inc. files with the SEC under CIK 1658551 (its SEC filings).
- Its shares are listed under the ticker AMLX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Amylyx Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Perceptive Advisors (filed 2026-05-15).
Who are Amylyx Pharmaceuticals, Inc.'s owners and officers?
Amylyx Pharmaceuticals, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-05-15).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 7.5% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Tcg Crossover Gp Ii, LLC | 5.7% |
| Schedule 13G/A, 2026-02-12 | Adage Capital Management, L.P. | 2.53% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 15% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 5.28% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 7.1% |
| Schedule 13G, 2025-11-17 | Commodore Capital LP | 5.1% |
| Schedule 13G/A, 2025-11-14 | Point72 Asset Management, L.P. | 2.6% |
| Schedule 13G/A, 2025-11-14 | Perceptive Advisors LLC | 8.2% |
| Schedule 13G/A, 2025-11-13 | Adage Capital Management, L.P. | 6.39% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 4.94% |
Questions about who owns Amylyx Pharmaceuticals, Inc.
Who owns Amylyx Pharmaceuticals, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Amylyx Pharmaceuticals, Inc.: Fmr LLC (15%, Schedule 13G/A, filed 2026-02-05), Perceptive Advisors LLC (7.5%, Schedule 13G/A, filed 2026-05-15), Blackrock, Inc. (7.1%, Schedule 13G/A, filed 2026-01-21), Tcg Crossover Gp Ii, LLC (5.7%, Schedule 13G/A, filed 2026-02-17) and Commodore Capital LP (5.1%, Schedule 13G, filed 2025-11-17).
Who are the largest shareholders of Amylyx Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Amylyx Pharmaceuticals, Inc. on this page are Fmr LLC (15%), Perceptive Advisors LLC (7.5%) and Blackrock, Inc. (7.1%).
When did Fmr LLC buy into Amylyx Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2026-02-05, reporting 15%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Amylyx Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Amylyx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Amylyx Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Amylyx Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 3,613,123 shares (2.8% of shares outstanding) (Form 4, 2026-09-14).
- , the chief executive and a director: 3,613,056 shares (2.8% of shares outstanding) (Form 4, 2026-09-14).
- , a director: 782,881 shares (0.61% of shares outstanding) (Form 4, 2026-10-07).
- , the chief medical officer: 278,064 shares (0.22% of shares outstanding) (Form 4, 2026-09-14).
- , the chief financial officer: 273,625 shares (0.21% of shares outstanding), 233,625 held directly and 40,000 indirectly (Form 4, 2026-09-14).
Shares outstanding: 128,562,904 as of 2026-10-26, from the company's latest SEC cover page.
How much has Amylyx Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Amylyx Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Amylyx Pharmaceuticals, Inc. and the records around it.
Amylyx Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/amylyx-pharmaceuticals